Figure 4
BEZ235-induced P-ERK pathway is prevented with agents inhibiting HER2 and MEK1/2 activity. (a) Immunoblots of lysates from BT474 and MCF7-HER2 cells treated with DMSO (c), BEZ235 (B, 500 nM) and lapatinib (L, 500 nM) or the combination of both inhibitors for 24 h. (b) Immunoblots of lysates from BT474 and MCF7-HER2 cells treated with DMSO (c), trastuzumab (T, 50 nM, 72 h) and BEZ235 (B, 100 nM, 24 h) or the combination of both. (c) Immunoblots of lysates from BT474 and MCF7-HER2 cells treated with AZD6244 and BEZ235 used at the indicated concentrations for 24 h. (d) Immunoblots of MCF7-HER2 cells treated with DMSO (c), BEZ235 (B, 500 nM) and lapatinib (L, 500 nM) as well as with erlotinib (E, 500 nM) and the indicated combinations for 24 h. All protein lysates were immunoblotted with the indicated antibodies.
